Quantitative 31P HR‐MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. Issue 6 (22nd July 2013)
- Record Type:
- Journal Article
- Title:
- Quantitative 31P HR‐MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. Issue 6 (22nd July 2013)
- Main Title:
- Quantitative 31P HR‐MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
- Authors:
- Esmaeili, Morteza
Bathen, Tone F.
Engebråten, Olav
Mælandsmo, Gunhild M.
Gribbestad, Ingrid S.
Moestue, Siver A. - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="mrm24869-sec-0001" sec-type="section"> <title>Purpose</title> <p>Phospholipid metabolites are of importance in cancer studies, and have been suggested as candidate metabolic biomarkers for response to targeted anticancer drugs. The purpose of this study was to develop a phosphorus (<sup>31</sup>P) high resolution magic angle spinning magnetic resonance spectroscopy protocol for quantification of phosphorylated metabolites in intact cancer tissue.</p> </sec> <sec id="mrm24869-sec-0002" sec-type="section"> <title>Methods</title> <p> <sup>31</sup>P spectra were acquired on a 14.1 T spectrometer with a triplet <sup>1</sup>H/<sup>13</sup>C/<sup>31</sup>P MAS probe. Quantification of metabolites was performed using the PULCON principle. Basal‐like and luminal‐like breast cancer xenografts were treated with the dual PI3K/mTOR inhibitor BEZ235, and the impact of treatment on the concentration of phosphocholine, glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine was evaluated.</p> </sec> <sec id="mrm24869-sec-0003" sec-type="section"> <title>Results</title> <p>In basal‐like xenografts, BEZ235 treatment induced a significant decrease in phosphoethanolamine (−25.6%, <italic>P</italic> = 0.01) whilst phosphocholine (16.5%, <italic>P</italic> = 0.02) and glycerophosphocholine (37.3%, <italic>P</italic> &lt; 0.001) were significantly increased. The metabolic changes could<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="mrm24869-sec-0001" sec-type="section"> <title>Purpose</title> <p>Phospholipid metabolites are of importance in cancer studies, and have been suggested as candidate metabolic biomarkers for response to targeted anticancer drugs. The purpose of this study was to develop a phosphorus (<sup>31</sup>P) high resolution magic angle spinning magnetic resonance spectroscopy protocol for quantification of phosphorylated metabolites in intact cancer tissue.</p> </sec> <sec id="mrm24869-sec-0002" sec-type="section"> <title>Methods</title> <p> <sup>31</sup>P spectra were acquired on a 14.1 T spectrometer with a triplet <sup>1</sup>H/<sup>13</sup>C/<sup>31</sup>P MAS probe. Quantification of metabolites was performed using the PULCON principle. Basal‐like and luminal‐like breast cancer xenografts were treated with the dual PI3K/mTOR inhibitor BEZ235, and the impact of treatment on the concentration of phosphocholine, glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine was evaluated.</p> </sec> <sec id="mrm24869-sec-0003" sec-type="section"> <title>Results</title> <p>In basal‐like xenografts, BEZ235 treatment induced a significant decrease in phosphoethanolamine (−25.6%, <italic>P</italic> = 0.01) whilst phosphocholine (16.5%, <italic>P</italic> = 0.02) and glycerophosphocholine (37.3%, <italic>P</italic> &lt; 0.001) were significantly increased. The metabolic changes could partially be explained by increased levels of phospholipase A2 group 4A (PLA2G4A).</p> </sec> <sec id="mrm24869-sec-0004" sec-type="section"> <title>Conclusion</title> <p> <sup>31</sup>P high resolution magic angle spinning magnetic resonance spectroscopy is a useful method for quantitative assessment of metabolic responses to PI3K inhibition. Using the PULCON principle for quantification, the levels of phosphocholine, glycerophosphocholine, phosphoethanolamine, and glycerophosphoethanolamine could be evaluated with high precision and accuracy. Magn Reson Med 71:1973–1981, 2014. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Magnetic resonance in medicine. Volume 71:Issue 6(2014:Jun.)
- Journal:
- Magnetic resonance in medicine
- Issue:
- Volume 71:Issue 6(2014:Jun.)
- Issue Display:
- Volume 71, Issue 6 (2014)
- Year:
- 2014
- Volume:
- 71
- Issue:
- 6
- Issue Sort Value:
- 2014-0071-0006-0000
- Page Start:
- 1973
- Page End:
- 1981
- Publication Date:
- 2013-07-22
- Subjects:
- Nuclear magnetic resonance -- Periodicals
Electron paramagnetic resonance -- Periodicals
616.07548 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1522-2594 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/mrm.24869 ↗
- Languages:
- English
- ISSNs:
- 0740-3194
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5337.798000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4208.xml